NEW YORK - C2i Genomics said on Tuesday that it is partnering with Twist Bioscience to develop whole-genome cancer reference materials for cancer detection.
Financial terms of the agreement were not disclosed.
Under the deal, C2i, a New York-based cancer diagnostic company, will use its artificial intelligence algorithm to identify variants across the genome that are associated with cancer signatures. Twist will then provide DNA synthesis for these variants to create a set of reference materials for whole-genome sequencing. The reference standard kits will be released by Twist as a product.
The reference standards will also be used to train C2i's algorithm for patient sample analysis. According to C2i, it has developed a way to use AI to detect "even the tiniest tumors" using whole-genome sequencing and machine learning.
"We expect that the development of this exceptionally robust set of reference standards for whole-genome sequencing will complement our cfDNA Pan-Cancer Reference Standards, which can be used in liquid biopsy assays," Emily Leproust, CEO and cofounder of Twist, said in a statement.
Last month, C2i entered a strategic partnership with Belgium-based precision medicine company OncoDNA to pair the company's AI-based whole-genome sequencing and minimal residual disease cancer monitoring platform with OncoDNA's European network of cancer clinician-researchers.